USA News Group – The American Cancer Society is projecting 2024 to be the first year ever for the US to have more than 2 million new cases, which would represent a record high. Among 10 of the most common...
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GILD),(NASDAQ:GTHX),(NASDAQ:AZN),(NASDAQ:HOLX) EQNX::TICKER_END
G1 Therapeutics (GTHX) delivered earnings and revenue surprises of 17.19% and 22.80%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
BioMarin (BMRN) delivered earnings and revenue surprises of 39.53% and 4.17%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
G1 Therapeutics (GTHX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
G1 Therapeutics (GTHX) delivered earnings and revenue surprises of 14.12% and 6.64%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Zymeworks Inc. (ZYME) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
G1 Therapeutics (GTHX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
/PRNewswire/ -- Simcere Pharmaceutical Group Limited (2096.HK) ("Simcere"), an innovative global biopharmaceutical company, and G1 Therapeutics, Inc., (Nasdaq:...
/PRNewswire/ -- USA News Group - A new study has revealed that women diagnosed with benign breast disease through screening have an almost double risk of...